Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

975.95 +2.15 (+0.22%)
Streaming Delayed Price Updated: 2:12 PM EDT, May 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Regeneron Pharmaceuticals

< Previous 1 2
...
25 26 27 28 29 30 31 32 Next >
Maravai Lifesciences Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating
Maravai Lifesciences sees its Relative Strength Rating enter the 80-plus level. 
Via Investor's Business Daily
Sanofi-Regeneron's COPD Drug Fails In Mid-Stage Trial, But Shows Potential Benefit In Subgroup of Former Smokers
Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) started their collaboration in chronic obstructive pulmonary disorder (COPD) to target all... 
Via Benzinga
Alnylam Pharmaceuticals Stock Sees Healthy Rising Relative Strength Rating
The Relative Strength (RS) Rating for Alnylam Pharmaceuticals stock climbed into a new percentile Monday, as it got a lift from 63 to 71. 
Via Investor's Business Daily
C4 Therapeutics Stock Enters Leadership Territory
A Relative Strength Rating upgrade for C4 Therapeutics shows improving technical performance. 
Via Investor's Business Daily
AMD And Biogen Lead The QQQ Lower Thursday
U.S. indices were trading lower Thursday as investors weigh Fed Chair Powell’s comments on inflation to the Senate banking panel. ... 
Via Benzinga
Topics Economy
Exposures Interest Rates
5 French Stocks To Consider For Bastille Day
Bastille Day is France’s National Day, celebrating the Storming of the Bastille on July 14, 1789, a key turning point in the French Revolution. And while the French concept... 
Via Benzinga
Is This Coronavirus Stock Undervalued?
This biotech giant might be down, but it isn't out just yet. 
Via The Motley Fool
Exposures COVID-19
2 Biotech Stocks That are Dirt Cheap Right Now
Biotech companies responded to the COVID-19 pandemic in a remarkable way, with vaccinations, treatments, diagnostics, and variant monitoring. 
Via Talk Markets
Exposures COVID-19
3 Top Biotech Stocks to Buy in July
Now's the time to get into these companies while their valuation is still favorable. 
Via The Motley Fool
Is It Too Late to Buy Intellia Therapeutics?
After skyrocketing 68% last week, will this stock keep running higher? 
Via The Motley Fool
Here's Why Regeneron Gained 11% Last Month
The biopharma outfit dropped news that may mean more for the medicine industry than anybody fully understands. 
Via The Motley Fool
Will an Increase in Vaccinations Hurt Regeneron's COVID Treatment Sales?
The antibody cocktail treats people with mild-to-moderate illness. 
Via The Motley Fool
Topics Cannabis
Exposures COVID-19 Cannabis
This News May Mean Billions for Regeneron
Regeneron's COVID-19 treatment is getting easier to administer -- and produce. 
Via The Motley Fool
Topics Cannabis
Exposures COVID-19 Cannabis
3 Tips for Coronavirus Investing Right Now
Whether you're a cautious or aggressive investor, there's something for you in this space. 
Via The Motley Fool
Topics Cannabis
Exposures COVID-19 Cannabis
Regeneron Discovers GPR75 Gene Mutations Can Protect Against Obesity, Begins Search For New Drugs
A team at Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Genetics Center has discovered mutations in the gene GPR75 that protect against obesity. Now, drug... 
Via Benzinga
Facebook And Nvidia Lead The QQQ Thursday
U.S. indices are trading higher following better-than-expected jobless claims, which lifted recovery sentiment to start off July. ... 
Via Benzinga
In Future CRISPR Gene Editing To Treat Diseases, Says Intellia Co-Founder: CNBC
Gene-editing technology CRISPR reached a significant milestone this week, completing its first systemic delivery as a medicine to the human body. What Happened: On Monday,... 
Via Benzinga
Can Intellia Therapeutics Turn Exciting Trial Results into Profits?
New proof-of-concept results are a big deal for the medical community, but what about for your portfolio? 
Via The Motley Fool
Exposures COVID-19
EC Selects Antibody Therapies, Arthritis Drug As Preferred COVID-19 Meds: Reuters
The European Commission (EC) picked four antibody treatments and a repurposed Eli Lilly And Co's (NYSE: LLY) rheumatoid arthritis drug for an initial... 
Via Benzinga
Exposures COVID-19
Why Regeneron Pharmaceuticals Analyst Says Competitive Concerns Are Overblown, Pipeline Opportunity Underappreciated
Regeneron Pharmaceuticals Inc.'s (NASDAQ:REGN) robust ... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 29, 2021
Upgrades For Nutrien Ltd (NYSE: 
Via Benzinga
Is Now The Time To Buy Stock In Tesla, GM Or Regeneron?
One of the most common questions traders have about stocks is “Why Is It Moving?” That’s why Benzinga created the Why I... 
Via Benzinga
Intellia Seeks To Raise $400M Via Equity
Intellia Therapeutics Inc (NASDAQ: NTLA) commenced an underwritten public offering of $400 million shares of its common stock. Underwriters have an option to... 
Via Benzinga
Facebook And Nvidia Lead The QQQ Higher Monday
The Nasdaq was trading sharply higher throughout Monday’s session amid a rebound in growth and tech names. The Inve... 
Via Benzinga
Ignoring Monday's 2 Big Nasdaq Winners Could Cost You Serious Money
Find out why these stocks are climbing higher. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Why Intellia Therapeutics Stock Is Skyrocketing Today
The company reported promising interim trial results for its CRISPR gene-editing candidate. 
Via The Motley Fool
Intellia Stock Leads Biotech Rally On Historic Moment For CRISPR
Intellia led a rally for CRISPR stocks on Monday on early promise for its gene-editing drug. The news sent NTLA stock to a record high. 
Via Investor's Business Daily
Why Intellia Therapeutics Stock Is Soaring Today
Intellia Therapeutics Inc (NASDAQ:NTLA) is trading signifi... 
Via Benzinga
Gene Editing Stocks: The Big News Lifting EDIT, BNGO, CRSP and NTLA Stocks
Gene editing stocks, led by NTLA stock, are powering higher on Monday following a landmark announcement by Intellia Therapeutics. 
Via InvestorPlace
Intellia Shares Shoot Higher On Promising Biomarker Data From CRISPR/Cas9 Genome Editing Candidate
Intellia Therapeutics Inc (NASDAQ: NTLA) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have announced positive interim data from an ongoing Phase 1... 
Via Benzinga
< Previous 1 2
...
25 26 27 28 29 30 31 32 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.